quality of life, and reduces functional impairment, fatigue, and impact of disease on work productivity in patients with active AS.
Ankylosing spondylitis (AS), part of the larger disease group of axial spondyloarthritis, is a chronic immune-mediated inflammatory disease (1, 2) . With an estimated worldwide prevalence of 0.2-1.4% (2-7), AS represents a significant personal, societal, and economic health-related burden. The progressive nature of AS can lead to structural damage of the spine, worsening of joint function, physical disability, and significant functional impairment, culminating in reduced healthrelated quality of life (HRQoL) (8) . Indeed, individuals with AS not only have pain and physical function limitations, but also experience diminished social functioning and work disability.
Traditional treatment options for patients with AS include nonsteroidal antiinflammatory drugs (NSAIDs) and physical therapy. However, over the long term, NSAID use is associated with gastrointestinal and cardiovascular adverse events, while disease-modifying antirheumatic drugs have been shown to have limited efficacy (9) in peripheral arthritis only and not in axial disease. Consequently, anti-tumor necrosis factor (anti-TNF) therapy is recommended in patients in whom NSAIDs fail to achieve adequate disease control or those patients with high disease activity, and these therapies have been shown to improve outcomes in patients with AS, reducing pain and improving mobility and HRQoL (9) . However, it has been reported that 25-40% of AS patients with moderate to severe disease do not respond to or are intolerant of anti-TNF agents and, therefore, are left with no alternative treatment (10) (11) (12) (13) (14) . Hence, there is an unmet need for novel therapies that offer long-term disease control in AS.
Therapeutic strategies targeting various inflammatory pathways, including interleukin-6 receptor (IL-6R) blockade, T cell costimulation inhibition, and IL-1R antagonism, have largely failed to show significant clinical efficacy in AS (12, 15, 16) . IL-17A has been implicated in the pathogenesis of AS, with elevated levels of IL-17-producing cells found in the circulation and target tissues of patients with this disease (17) (18) (19) .
Secukinumab (AIN457) is a high-affinity, fully human IgG1k monoclonal antibody that selectively binds to and neutralizes IL-17A. In a phase II proof-ofconcept trial, secukinumab was well tolerated and rapidly reduced clinical and biologic signs of active AS (20) . MEASURE 1 is an ongoing, 2-year, phase III, randomized trial, followed by a 3-year extension period, designed to assess the long-term efficacy and safety of secukinumab in patients with active AS. Secukinumab was shown to improve the signs and symptoms of AS through the first 52 weeks of therapy (21) . Here, we report the effects of secukinumab treatment over 52 weeks on patient-reported outcomes.
PATIENTS AND METHODS
Study design and patients. The detailed study design and methods for MEASURE 1 have been described previously (21) . Briefly, eligible patients were ages $18 years and were diagnosed as having AS with prior documented radiologic evidence fulfilling the modified New York criteria (22) and active disease defined as a score of $4 on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (23) and spinal pain $4 cm on a 10-cm visual analog scale at baseline, despite treatment with maximum tolerated doses of NSAIDs. Key exclusion criteria included total spinal ankylosis, evidence of infection or malignancy on chest radiograph, and previous treatment with cell-depleting therapies or biologic agents other than anti-TNF therapy (21) . The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Institutional review board or ethics committee approval and written informed consent from patients were obtained prior to study procedures being initiated. This study is registered with ClinicalTrials.gov (identifier NCT01358175).
This phase III double-blind, placebo-controlled study was conducted at 65 centers across Belgium, Bulgaria, Canada, France, Germany, Italy, Mexico, The Netherlands, Peru, Russia, Taiwan, Turkey, the UK, and the US. Patients were randomized (1:1:1) to receive intravenous (IV) secukinumab 10 mg/kg (at baseline and weeks 2 and 4) followed by subcutaneous (SC) secukinumab 150 mg, or 75 mg every 4 weeks (IV!150 mg group and IV!75 mg group, respectively), or placebo on the same IV and SC dosing schedule. Responders were defined as patients in whom Assessment of SpondyloArthritis international Society criteria for 20% improvement in disease activity (ASAS20) was achieved. In those patients who were originally assigned to receive placebo at baseline, nonresponders and responders were re-randomized (1:1) to receive secukinumab 150 mg SC or 75 mg SC at weeks 16 and 24, respectively.
Patient-reported outcome assessments. A brief overview of the patient-reported outcomes assessed in this study is presented in Table 1 . The patient-reported outcomes were assessed as prespecified end points and included mean change from baseline to weeks 16 and 52 in the BASDAI (21,23), Short Form 36 (SF-36) health survey physical component summary (PCS) score (21, 24) , SF-36 mental component summary (MCS) score (24) , Ankylosing Spondylitis Quality of Life (ASQoL) measure (21, 25) , Bath Ankylosing Spondylitis Functional Index (BASFI) (26), EuroQol 5-domain (EQ-5D) questionnaire (27) , Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) (28, 29) , and Work Productivity and Activity Impairment-General Health (WPAI-GH) (30) ( Table  1) . Additional assessments included the proportion of patients in whom BASDAI 50 was achieved (defined as at least a 50% improvement [decrease] from baseline in the total BASDAI score) and the proportion of patients with improvements from baseline in the SF-36 PCS and MCS that exceeded the minimum clinically important difference (MCID; defined as an improvement of $2.5 points) at week 16 and other time points. Patients in whom such an improvement was achieved are referred to here as SF-36 PCS or MCS responders.
BASDAI and BASFI were assessed at baseline and at weeks 1, 2, and 4, then every 4 weeks to week 32, and then at weeks 40 and 52. All other patient-reported outcomes were assessed at baseline and weeks 4, 8, 12, 16, 24, and 52, except for the WPAI-GH, which was assessed at baseline and weeks 16, 24, and 52.
Statistical analysis. Sample size calculation and detailed statistical analyses for primary and secondary end points have been reported previously (21) . All of the patientreported outcomes were analyzed in the full analysis set that comprised all patients from the randomized set who had been assigned to receive study treatment. The difference between secukinumab and placebo treatment for continuous variables at weeks 16 and 52 in patient-reported outcomes (except WPAI-GH, which was analyzed using observed data) were analyzed using mixed-effects model repeated measures (MMRM), with treatment groups, visit, and anti-TNF status as factors, and respective baseline score and weight as covariates. Treatment-byvisit and respective baseline score-by-visit were included as interaction terms. An unstructured covariance structure was assumed for the model. The significance of the treatment effects for secukinumab regimens at different analysis visits was determined from the pairwise comparisons performed between secukinumab regimens and placebo.
A subgroup analysis assessed BASDAI, SF-36 PCS, and ASQoL, which were part of the predefined testing strategy, according to previous anti-TNF status (patients who were naive for anti-TNF therapy or those with a history of inadequate response to or intolerance of these agents). The 
RESULTS
Characteristics of the patients. Between November 9, 2011 and January 21, 2013, a total of 371 patients with AS were randomized to 1 of the 3 treatment groups: secukinumab IV!150 mg (n 5 125), secukinumab IV!75 mg (n 5 124), or placebo (n 5 122). A countryspecific breakdown of enrolled patients is available upon request from the corresponding author. Of the 371 patients randomized, 351 (94.6%) remained in the study at week 16 and 319 (86.0%) remained in the study at week 52.
Baseline demographics, disease characteristics, and prior or concomitant medication use were similar across study groups (Table 2 ) and have been reported in detail elsewhere (21) . Mean SF-36 PCS scores at baseline ranged from 36.3 to 37.6 across the treatment groups, and ASQoL scores ranged from 10.8 to 11.7, indicating impaired physical function and HRQoL (Table 3) .
Patient-reported outcomes. At week 16, improvements in the BASDAI score were significantly greater in patients receiving either regimen of secukinumab than in those receiving placebo (21) . The LSM changes in both secukinumab regimens also exceeded MCID values (Table 1) . Additionally, the OR (.1) favored a higher BASDAI 50 response with both secukinumab regimens versus placebo (Figure 1) . Improvements in the total BASDAI score were sustained through week 52 ( Figure 2A and Table 3 ) (21) . Furthermore, at week 16, LSM change from baseline in the BASDAI score was greater in patients treated with secukinumab than in those treated with placebo regardless of hsCRP level at baseline. In patients with hsCRP levels #10 mg/liter, LSM 6 SEM changes from baseline to week 16 were 21.9 6 0.2 in those 
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Patients treated with secukinumab also showed improvements in the total BASDAI score at weeks 16 and 52 (21) irrespective of anti-TNF status (naive versus inadequate response). At week 16, LSM 6 SEM changes from baseline in anti-TNF-naive patients were 22.7 6 0.2 in patients treated with secukinumab IV!150 mg and 22.6 6 0.2 in patients treated with secukinumab IV!75 mg versus 20.7 6 0.2 in patients treated with placebo (both P , 0.0001). For patients with an inadequate response to anti-TNF agents, changes from baseline to week 16 were 21.7 6 0.3 in those treated with secukinumab IV!150 mg and 22.2 6 0.3 in those treated with secukinumab IV!75 mg versus 20.7 6 0.3 in those treated with placebo (P , 0.05 for secukinumab IV!150 mg versus placebo and P , 0.01 for secukinumab IV!75 mg versus placebo). At week 52, further improvements in the BASDAI score were observed in patients treated with secukinumab who were anti-TNF naive (mean 6 SD change from baseline 23.3 6 2.3 with secukinumab IV!150 mg and 22.9 6 1.9 with secukinumab IV!75 mg) and those who had an inadequate response to anti-TNF agents (mean 6 SD change 2.8 6 1.9 with secukinumab IV!150 mg and 22.7 6 1.9 with secukinumab IV!75 mg).
At week 16, improvements in SF-36 PCS and ASQoL were also significantly greater in patients treated with either secukinumab regimen compared with those treated with placebo (21) . Improvements in SF-36 PCS and ASQoL exceeded MCID values and were sustained through 52 weeks with both secukinumab regimens (Figures 2B and C and Table 1 ). The OR favored higher SF-36 PCS and MCS responses in patients treated with either secukinumab regimen versus those treated with placebo, although the P values for SF-36 MCS were .0.05 for both secukinumab regimens (Figure 1 ). Greater ASAS20 and ASAS40 response rates with secukinumab versus placebo (21) were also indicated by the ORs (.1 for both parameters), which are also shown for comparison (Figure 1) .
Both anti-TNF-naive patients and those with an inadequate response to anti-TNF showed improvements in SF-36 PCS and ASQoL. For anti-TNF-naive patients, LSM 6 SEM changes in SF-36 PCS from baseline to week 16 were 6.9 6 0.6 in those treated with secukinumab IV!150 mg and 6.1 6 0.7 in those treated with secukinumab IV!75 mg versus 1.3 6 0.7 in those treated with placebo (both P , 0.0001). For patients with an inadequate response to anti-TNF agents, LSM 6 SEM changes in SF-36 PCS from baseline to week 16 were 3.6 6 1.2 in those treated with secukinumab IV!150 mg and 6.5 6 1.2 in those treated with secukinumab IV!75 mg versus 2.0 6 1.3 in those treated with placebo (P 5 0.35 for secukinumab IV!150 mg versus placebo and P , 0.05 for secukinumab IV!75 mg versus placebo). At week 52, further improvement in SF-36 PCS was observed with secukinumab IV!150 mg in patients in both subgroups and with secukinumab IV!75 mg in anti-TNF-naive patients. The mean 6 SD change from baseline to week 52 was 8.3 6 7.4 in anti-TNF-naive patients treated with secukinumab IV!150 mg, 7.1 6 6.2 in anti-TNF-naive patients treated with secukinumab IV!75 mg, 4.9 6 6.2 in patients with an inadequate response to anti-TNF agents treated with secukinumab IV!150 mg, and 6.8 6 7.8 in patients with an inadequate response to anti-TNF agents treated with secukinumab IV!75 mg.
The LSM 6 SEM changes from baseline to week 16 in ASQoL in the anti-TNF-naive subgroup were 24.4 6 0.5 in patients treated with secukinumab IV! 150 mg and 23.7 6 0.5 in patients treated with secukinumab IV!75 mg versus 21.3 6 0.5 in patients treated with placebo (P , 0.0001 for secukinumab IV!150 mg versus placebo and P , 0.001 for secukinumab IV!75 mg versus placebo). In the subgroup of patients with an inadequate response to anti-TNF, the LSM 6 SEM changes from baseline to week 16 were 21.9 6 0.9 in patients treated with secukinumab IV!150 mg and 24.4 6 0.9 in patients treated with secukinumab IV!75 mg versus 21.0 6 0.9 in patients treated with placebo (P 5 0.47 for secukinumab IV!150 mg versus placebo and P , 0.01 for secukinumab IV!75 versus placebo). These scores were similar or improved with both secukinumab regimens at week 52. The mean 6 SD change from baseline to week 52 was 25.0 6 5.3 in anti-TNF-naive patients treated with secukinumab IV!150 mg, 24.1 6 4.3 in anti-TNF-naive patients treated with secukinumab IV!75 mg, 23.4 6 3.9 in patients with an inadequate response to anti-TNF agents treated with secukinumab IV!150 mg, and 25.7 6 5.3 in patients with an inadequate response to anti-TNF agents treated with secukinumab IV!75 mg.
Mean changes from baseline to week 16 for the BASFI (Figure 3) , EQ-5D, and FACIT-F were greater in patients treated with either secukinumab regimen than in those treated with placebo (Table 3) . Improvements in BASFI and EQ-5D also exceeded MCID values in patients treated with secukinumab ( Table 1) .
The percent of work time missed due to health decreased from baseline to week 16 in patients treated with secukinumab and increased in patients treated with placebo (21.0% in patients treated with secukinumab IV!150 mg and 23.9% in patients treated with secukinumab IV!75 mg versus 1.9% in patients treated with placebo). Similarly, percentage improvements from baseline to week 16 in all other WPAI-GH outcomes (impairment while working due to health, overall work impairment due to health, and activity impairment due to health) were also greater in patients treated with secukinumab than in those treated with placebo. All of these outcomes were sustained or further improved through week 52 in both secukinumab groups.
DISCUSSION
The 52-week results from the MEASURE 1 study showed significant and sustained improvements in the signs and symptoms of AS with secukinumab (21). The patient-reported outcomes assessed in MEASURE 1 showed that in addition to significant and sustained improvement in the signs and symptoms of AS (21) , patients treated with secukinumab showed statistically and clinically significant improvements in multiple facets of physical functioning and HRQoL at week 16 compared with those treated with placebo. The improvements were sustained in the secukinumab regimens over the long term, i.e., through week 52.
These results are clinically meaningful, since patients with active AS experience poor HRQoL due to back pain, discomfort, and fatigue, which ultimately restricts their physical function and work productivity (31) . The significant improvements observed with both secukinumab regimens versus placebo at week 16 in BASDAI, SF-36 PCS, and ASQoL (21) were maintained irrespective of the baseline anti-TNF status of the patients. Improvements in BASDAI scores were also better with secukinumab versus placebo at week 16 regardless of baseline hsCRP level and were sustained up to week 52. All improvements observed at week 16 were sustained through week 52, and the OR favored better responses with the 2 secukinumab regimens versus placebo.
Both secukinumab regimens provided improvements in BASFI scores and all 5 domains of health status on the EQ-5D in comparison to placebo, suggesting improvements in the physical function and health status of the patients receiving secukinumab.
Patients with AS frequently experience fatigue due to pain, stiffness, and poor sleep (32, 33) . Although the impact of fatigue on patients with AS has not been a prominent focus of clinical research in the past, recent research has established the impact of treatment on this important patient-reported outcome (34, 35) . However, only a few AS studies have directly assessed fatigue using a focused tool, such as the FACIT-F scale, and considered fatigue as a major symptom in the majority of patients with AS (32, 36, 37) . In the current trial, secukinumab treatment resulted in a greater reduction in fatigue and impact of AS on daily activities and function at week 16 than placebo, as measured by the FACIT-F scale. Moreover, the higher maintenance dose used in the secukinumab IV!150 mg arm resulted in further reductions in FACIT-F score as well as improvements in daily activities and function at week 52.
The disabling nature of AS may also lead to premature withdrawal from active employment and a decrease in work productivity (38) . In our study, greater reductions in work or activity impairment at week 16, as assessed by WPAI-GH, were observed with secukinumab than with placebo, and sustained or further improvements were noted at week 52.
A limitation of this study concerns the methodology used to assess the statistical significance of differences in mean patient-reported outcome score changes across groups. Although the use of all patient-reported outcome assessments was prespecified in the study, only the changes from baseline in the BASDAI, SF-36 PCS, and ASQoL were included in the predefined hierarchical testing strategy that accounted for increases in Type I error due to multiple testing. However, consistent trends in improvements across multiple patientreported outcome measures assessing several disease dimensions reflect the clinically meaningful impact of secukinumab treatment on AS.
Secukinumab is the first biologic agent other than TNF inhibitors to demonstrate significant improvements in the signs and symptoms of AS in a phase III trial. The additional results from MEASURE 1 presented here build on these findings to show that secukinumab provided significant and sustained improvements in patientreported disease activity, HRQoL, functional impairment, physical and mental health status, fatigue levels, and work productivity in patients with active AS.
